drotrecogin alfa

Home
Ligands
drotrecogin alfa

GtoPdb Ligand ID: 6788

Synonyms: drotrecogin alfa (activated) | HSDB 7366 | Xigris®

drotrecogin alfa is an approved drug (FDA (2001), EMA (2009))

Compound class: Peptide or derivative

Comment: Drotrecogin alfa (activated) is a recombinant form of human activated protein C.

Summary
Biological activity
Clinical data
References
Structure

No information available.

No information available.

Summary of Clinical Use
In the USA drotrecogin was FDA approved for the reduction of mortality in adult patients with severe sepsis, but was withdrawn (2011) due to a failure to show a survival benefit for patients with severe sepsis and septic shock

Summary of Clinical Use

In the USA drotrecogin was FDA approved for the reduction of mortality in adult patients with severe sepsis, but was withdrawn (2011) due to a failure to show a survival benefit for patients with severe sepsis and septic shock

Mechanism Of Action and Pharmacodynamic Effects
Endogenous activated protein C exerts its antithrombotic effect by inhibiting blood coagulation factors Va and VIIIa. Drotrecogin alfa (activated) acts in the same way to produce its anti-thrombotic, anti-inflammatory, and profibrinolytic properties.

Mechanism Of Action and Pharmacodynamic Effects

Endogenous activated protein C exerts its antithrombotic effect by inhibiting blood coagulation factors Va and VIIIa. Drotrecogin alfa (activated) acts in the same way to produce its anti-thrombotic, anti-inflammatory, and profibrinolytic properties.